bioRxivCancer Biology
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming.
A. Velez-Delgado, K. L. Donahue, K. L. Brown, W. Du, V. Irizarry-Negron, R. E. Menjivar, E. L. Lasse-Opsahl, N. G. Steele, S. The, J. Lazarus, V. R. Sirihorachai, W. Yan, S. B. Kemp, S. A. Kerk, M. Bollamplly, F. Lima, C. A. Lyssiotis, A. Rao, H. C. Crawford, F. Bednar, T. L. Frankel, Y. Zhang, M. Pasca di Magliano
Abstract
Oncogenic KRAS is the hallmark mutation of human pancreatic cancer and a driver of tumorigenesis in genetically engineered mouse models of the disease. While the tumor cell-intrinsic effects of oncogenic Kras expression have been widely studied, its role in regulating the extensive pancreatic tumor microenvironment is less understood. Using a genetically engineered mouse model of inducible and reversible oncogenic Kras expression and a combination of approaches that include mass cytometry and single cell RNA sequencing, we have discovered that non-cell autonomous (i.e., extrinsic) oncogenic KRAS signaling reprograms pancreatic fibroblasts, activating an inflammatory gene expression program. As a result, fibroblasts become a hub of extracellular signaling, mediating the polarization and function of pro-tumorigenic myeloid cells while also preventing tissue repair. Our study provides fundamental new knowledge on the mechanisms underlying the formation of the fibroinflammatory stroma in pancreatic cancer and highlights stromal pathways with the potential to be exploited therapeutically.
- organism: mouse
- assay: bulk RNA-seq
- assay: multiome
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Modulation of fibroblasts phenotype by colorectal cancer cells-secreted factors is mostly independent of oncogenic KRAS
P. Dias Carvalho, S. Mendonca, … S. Velho·CellsPeer-reviewed·Aug 11, 2022
- Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer
S. Bhattacharyya, C. Oon, … M. H. Sherman·bioRxiv·Jul 22, 2019
- Mutant KRAS promotes NF-kB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma
Donovan Drouillard, Marissa Davies, … Michael B. Dwinell·bioRxiv·Apr 15, 2026
- Ductal pancreatic cancer interception by FGFR2 abrogation
Claudia Tonelli, Astrid Deschênes, … David Arthur Tuveson·Cancer ResearchPeer-reviewed·Apr 2, 2025
- Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity
S. K. Fey, A. K. Najumudeen, … O. J. Sansom·bioRxiv·Aug 29, 2023
- Prevention and reversion of pancreatic tumorigenesis through a differentiation-based mechanism
N. M. Krah, D. Yugawa, … L. C. Murtaugh·bioRxiv·Nov 19, 2017